Table 1. Patient characteristics.
| No. | Subtype | Clinical Stage | Neoadjuvant chemotherapy | Surgical stage | RCBh score | RCB class |
|---|---|---|---|---|---|---|
| 4 | TNBC a | 3A | Paclitaxel*12->ACd*4 | 1 | 1.333 | 1 |
| 8 | TNBC | 3A | AC*4 -> De*4 | 0 (pCRg) | 0 | 0 |
| 9 | ERb-HER2c+ | 3C | AC*4 -> DHf*4 | 2A | 1.315 | 1 |
| 11 | TNBC | 2B | AC*4 -> D*4 | 1 | 1.630 | 2 |
| 13 | TNBC | 2B | Paclitaxel*12->AC*4 | 1 | 0.748 | 1 |
| 14 | ER+HER2- | 3C | AC*4 -> D*4 | 3A | 2.559 | 2 |
| 20 | TNBC | 3C | AC*4 -> D*4 | 1 | 2.132 | 2 |
| 21 | ER+HER2- | 2B | AC*4 -> D*4 | 1 | 1.797 | 2 |
| 23 | TNBC | 3B | AC*4 -> D*4 | 3A | 4.090 | 3 |
| 24 | ER-HER2+ | 3A | AC*4 -> DH*4 | 2B | 3.922 | 3 |
| 28 | TNBC | 2B | AC*4 -> D*4 | 2A | 1.675 | 2 |
| 29 | TNBC | 3A | Paclitaxel*12->AC*4 | 2B | 3.428 | 3 |
| 32 | TNBC | 2B | AC*4 -> D*4 | 2B | 3.310 | 3 |
| 34 | TNBC | 3A | AC*4 -> D*4 | 0 | 0 | 0 |
| 35 | TNBC | 3A | AC*4 -> D*4 | 0 | 0 | 0 |
a: triple-negative breast cancer; b: estrogen receptor; c: human epidermal receptor 2; d: adriamycin+cyclophosphamide; e: docetaxel; f: docetaxel+herceptin; g: pathologic complete response; h: residual cancer burden.